“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with zero ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association. Laura M. Mann ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

July 23, 2024 — Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global ...

Now more than 40 years since the discovery of the HIV pandemic. 8 The results of this study provide reason for optimism that offering long-acting antiretroviral options for PrEP, as part of a flexible ...

The Centers for Disease Control and Prevention (CDC) has announced the five health departments that will receive federal funding to provide generic pre-exposure prophylaxis (PrEP) to prevent HIV as ...

Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...

How Was It Studied for the Prevention of HIV? Two large studies were conducted to see if Apretude is safe and effective as a PrEP regimen in people at risk of getting HIV. In both studies ...

One of the most important medical breakthroughs in the fight against HIV has been the use of antiretroviral treatments for prevention. Called pre-exposure prophylaxis (PrEP), this is commonly ...

The deal gives the go-ahead for the production and distribution of Gilead’s PrEP injectable lenacapavir. The royalty-free initiative aims to accelerate access to this vital HIV prevention tool in 120 ...